CEO Ivana Magovčević-Liebisch led Vigil Neuroscience through its acquisition by Sanofi. Now, she’s heading up another neuroscience company: Draig Therapeutics. She’ll break down how the Vigil deal came together and how she decided what came next.

Join us for a conversation with Shreehas Tambe, CEO and MD of Biocon Biologics. We’ll explore his vision for the future of biosimilars, the barriers that must be overcome to expand access, and the promise biosimilars have to deliver critical, affordable medicines for the world's most pressing healthcare needs, including diabetes care and the rapidly growing “diabesity” market.

AI is everywhere in biopharma. But it’s everywhere else, too — and the talent wars are on. Can the biopharma industry compete with big tech?

Catalent President and CEO, Alessandro Maselli, and John Carroll will look ahead at what might be coming for biotech in 2026. Hear their predictions for the industry's next year.

Hear from the newly minted Nobel winner about his award-winning research and the relationship between biotech and basic science.

Biotech in 2025 was anything but predictable. Market volatility, regulatory shifts, and financing headwinds have reshaped the industry, demanding bold leadership. Join Marianne De Backer, CEO of Vir Biotechnology, as she shares how Vir Bio is navigating uncertainty in the macroenvironment while driving corporate evolution and charting a course in immune-oncology.

Endpoints readers are the most in-the-know group of biopharma leaders around — and they’re sharing their perspectives through our new Biopharma Sentiment Index. We’ll share exclusive insights from the survey about where experts think the industry is and where it's going.

Prolific Machines' light-controlled platform unlocks breakthroughs in manufacturability, COGS and even therapeutic performance. Based on Prolific’s work across active pipeline programs, CEO and Co-Founder, Deniz Kent, will explain why light-controlled manufacturing is inevitable for highly efficacious, complex biologics to reach patients — and how integrating this plug-in technology can give asset owners and CDMOs a decisive edge in developing next-generation pipelines.

To view materials from this Executive Spotlight, click here.

Gilead Sciences is pursuing an ambitious vision: to deliver more than ten transformative therapies by 2030. Join Gilead’s Chief Medical Officer, Dietmar Berger, MD, PhD, for a conversation on how the company is broadening and diversifying its portfolio across virology, oncology and inflammation. He’ll discuss Gilead’s strategic evolution, from its long-standing leadership in HIV and viral hepatitis to its growing strength in cancer and inflammatory diseases.

China’s leading drug developer, Jiangsu Hengrui Pharmaceuticals, has spent the past year doing deals with US and European companies. We’ll talk with Chief Strategy Officer Frank Jiang about how the company is thinking about its role on the global stage.

ARCH Venture Partners Co-Founder Robert Nelsen is one of biotech’s most prolific and outspoken investors. He’ll sit down with Endpoints News to share his outlook on the industry’s biggest issues — from AI to China — and look ahead to next year.

Join Endpoints reporters and editors to recap the JPM conference and make predictions for the year ahead.

Join us for an invite-only networking reception and live taping of the Post-Hoc Live podcast as we wrap up our Endpoints at #JPM26 programming. Connect with colleagues and our newsroom to compare notes from the week’s sessions and share early takeaways over drinks and light bites. RSVP required.